Post hoc analysis revealed significantly better performances in AD patients carrying higher levels of natural anti-NMDAR1 autoantibodies than in AD patients carrying lower levels of natural anti-NMDAR1 autoantibodies in either Verbal Fluency Correct Response (In female AD patients, Welch’s t-test, t= 2.1227, p=0.04; in male AD patients, Welch’s t-test, t= 2.0938, p=0.042) or Verbal Fluency Total Words (In female AD patients, Welch’s t-test, t=1.8743, p=0.069; in male AD patients, Welch’s t-test, t= 2.253, p=0.029). The gene discussed is GRIN1; the disease is Alzheimer disease.